Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
NCT04205968Phase 2Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Jun 2020
- Primary completion
- Feb 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ramucirumab in small bowel adenocarcinoma (SBA) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Progression-Free Survival up to 3 years. Started Jun 2020; status: recruiting.
02
Drugs
ramucirumab
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT04205968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205968.